GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zhejiang Taimei Medical Technology Co 2576.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

4.40

+1.85%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥581.4m

FY2021FY2025

Net income

−CN¥48.6m

FY2021FY2025

Free cash flow

−CN¥50.2m

FY2021FY2025

Shareholders' equity

CN¥1.31bn

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
RevenueCN¥581.4mCN¥551.2mCN¥573.1mCN¥549.2mCN¥542.9m
Gross profitCN¥246.8mCN¥224.9mCN¥179.0mCN¥185.4mCN¥190.5m
Research and developmentCN¥89.2mCN¥87.1mCN¥169.2mCN¥233.7mCN¥262.1m
Operating income−CN¥71.6m−CN¥252.5m−CN¥396.6m−CN¥442.8m−CN¥588.8m
Net income−CN¥48.6m−CN¥214.6m−CN¥346.8m−CN¥412.9m−CN¥558.5m
Diluted earnings per share-0.09-0.38-0.62-0.74-1.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assetsCN¥1.81bnCN¥1.58bnCN¥1.44bnCN¥1.83bnCN¥2.10bn
Cash and short-term investmentsCN¥1.39bnCN¥1.20bnCN¥1.07bnCN¥1.41bnCN¥1.63bn
Total liabilitiesCN¥425.8mCN¥348.6mCN¥402.6mCN¥442.0mCN¥458.5m
DebtCN¥71.2mCN¥34.8mCN¥15.1mCN¥45.9mCN¥77.4m
Shareholders' equityCN¥1.31bnCN¥1.16bnCN¥978.3mCN¥1.31bnCN¥1.64bn
Shares outstanding564m564m560m560m560m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operations−CN¥45.9m−CN¥201.6m−CN¥351.2m−CN¥329.2m−CN¥253.3m
Capital spending−CN¥4.4m−CN¥6.2m−CN¥9.5m−CN¥28.2m−CN¥37.7m
Free cash flow−CN¥50.2m−CN¥207.8m−CN¥360.6m−CN¥357.4m−CN¥291.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Dec 2024Jun 2024Mar 2024
RevenueCN¥153.5mCN¥153.5mCN¥156.2mCN¥156.2mCN¥284.4mCN¥551.2mCN¥163.9mCN¥132.1m
Gross profitCN¥68.6mCN¥68.6mCN¥68.3mCN¥68.3mCN¥116.7mCN¥224.9mCN¥71.5mCN¥49.5m
Operating income−CN¥36.3m−CN¥36.3m−CN¥21.4m−CN¥21.4m−CN¥56.7m−CN¥252.5m−CN¥83.6m−CN¥126.7m
Net income−CN¥26.3m−CN¥26.3m−CN¥11.7m−CN¥11.7m−CN¥26.6m−CN¥214.6m−CN¥63.9m−CN¥116.3m
Diluted earnings per share-0.05-0.05-0.02-0.02-0.05-0.38-0.11-0.21
Cash from operations——CN¥4.0mCN¥4.0m—−CN¥201.0m−CN¥23.0m−CN¥112.0m
Capital spending——−CN¥1.0m−CN¥1.0m—−CN¥5.0m——
Free cash flow——CN¥3.0mCN¥3.0m—−CN¥206.0m——
Total assetsCN¥1.75bnCN¥1.75bnCN¥1.81bnCN¥1.81bnCN¥1.77bnCN¥1.58bn—CN¥1.56bn
Cash and short-term investmentsCN¥1.26bnCN¥1.26bnCN¥1.39bnCN¥1.39bnCN¥1.34bnCN¥1.20bn—CN¥1.14bn
DebtCN¥98.1mCN¥98.1mCN¥71.2mCN¥67.6mCN¥21.9mCN¥23.3m—CN¥30.6m
Shareholders' equityCN¥1.26bnCN¥1.26bnCN¥1.31bnCN¥1.31bnCN¥1.33bnCN¥1.16bn—CN¥1.10bn

Financial ratios

Data as of 27 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin42.4%40.8%31.2%33.8%35.1%41.0%
Operating margin-9.7%-39.3%-61.9%-76.5%-102.3%-163.5%
Net margin-8.4%-38.9%-60.5%-75.2%-102.9%-173.1%
Return on equity-3.7%-18.5%-35.4%-31.5%-34.0%-30.8%
Return on assets-2.7%-13.6%-24.0%-22.6%-26.6%-27.3%
Free cash flow yield-1.6%-8.6%-14.7%-13.8%-9.6%—
Revenue growth-9.4%-3.8%4.4%17.8%53.9%61.7%
Earnings growth-80.6%-38.1%-16.0%-13.9%-8.5%34.9%
Current ratio4.47x5.05x3.71x4.24x4.55x8.24x
Debt to equity0.05x0.02x0.03x0.05x0.03x0.01x
Equity ratio72.1%73.1%67.7%71.8%78.2%88.5%
Interest coverage-59.87x-298.04x-248.03x-156.62x-176.04x—
R&D as a share of sales15.3%15.8%29.5%42.5%48.3%36.0%
Buybacks as a share of market value-2.5%1.9%0.0%-5.6%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue1.9%——
Operating income-45.5%——
Net income-51.0%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin41.6%37.1%——

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings-41.3-10.6
Price to sales3.54.1

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.